A medical venture focused on developing program-based medical devices using uniquely analyzed vital data.
Currently developing a diabetes treatment app called “glucose flight,” which features AI-powered automatic blood glucose level prediction for patients with type 2 diabetes.
Our mission is to “design next-generation treatments with digital therapeutics.”

We offer early disease diagnosis services based on gene expression analysis technology primarily using RNA derived from blood.
Our main services include the manufacture and sale of the pancreatic cancer test kit “PanRegza® (Approval Number 30400EZX00046000)” and contract analysis services.